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Abstract
Aims Cardiomyopathies comprise a heterogeneous group of diseases, often of genetic origin. We assessed the current prac-
tice of genetic counselling and testing in the prospective European Society of Cardiology EURObservational Research Pro-
gramme Cardiomyopathy Registry.
Methods and results A total of 3208 adult patients from 69 centres in 18 countries were enrolled. Genetic counselling was
performed in 60.8% of all patients [75.4% in hypertrophic cardiomyopathy (HCM), 39.2% in dilated cardiomyopathy (DCM),
70.8% in arrhythmogenic right ventricular cardiomyopathy (ARVC), and 49.2% in restrictive cardiomyopathy (RCM),
P < 0.001]. Comparing European geographical areas, genetic counselling was performed from 42.4% to 83.3% (P < 0.001).
It was provided by a cardiologist (85.3%), geneticist (15.1%), genetic counsellor (11.3%), or a nurse (7.5%) (P < 0.001). Genetic
testing was performed in 37.3% of all patients (48.8% in HCM, 18.6% in DCM, 55.6% in ARVC, and 43.6% in RCM, P < 0.001).
Index patients with genetic testing were younger at diagnosis and had more familial disease, family history of sudden cardiac
death, or implanted cardioverter defibrillators but less co‐morbidities than those not tested (P < 0.001 for each comparison).
At least one disease‐causing variant was found in 41.7% of index patients with genetic testing (43.3% in HCM, 33.3% in DCM,
51.4% in ARVC, and 42.9% in RCM, P = 0.13).
Conclusions This is the first detailed report on the real‐life practice of genetic counselling and testing in cardiomyopathies in
Europe. Genetic counselling and testing were performed in a substantial proportion of patients but less often than recom-
mended by European guidelines and much less in DCM than in HCM and ARVC, despite evidence for genetic background.
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Introduction
Cardiomyopathies are a heterogeneous group of diseases
characterized by abnormal function and structure of the car-
diac muscle not caused by hypertension, coronary artery dis-
ease, valvular defects, or congenital heart disease.1,2 As a
disease group, cardiomyopathies are an important cause of
heart failure, arrhythmias, and sudden cardiac death (SCD).
As genetic causes explain a substantial proportion of cardio-
myopathies, patients need dedicated genetic counselling, in-
formation about the risk of inheritance, and organized
cardiac family screening and diagnostic genetic testing in
the context of family cascade screening strategy to improve
the management of patients and the family. The expected
clinical benefit has been translated into various guidelines
or position statements since 2010, with a high level of recom-
mendation, so that genetic counselling and testing of these
patients have rapidly diffused into the cardiology
community.3–6 However, economical and organizational as-
pects may affect the implementation of these recommenda-
tions, and there are few data on the current practices of
genetic counselling and testing of these patients, especially
in the era of next‐generation sequencing.
The EURObservational Research Programme Cardiomyopa-
thy Registry, initiated by the European Society of Cardiology
(ESC) Working Group on Myocardial and Pericardial Diseases,
was conducted to provide real‐life data on the current prac-
tices and management of patients with cardiomyopathies
and myocarditis from a large number of specialized centres.7,8
The main objectives of this ancillary study were (i) to eval-
uate how often genetic counselling and testing are per-
formed in real life and (ii) to understand heterogeneous
practices and search for predictors of these practices. To an-
alyse the yield of genetic testing was only a secondary and ex-
ploratory objective because of heterogeneous molecular
analyses performed by centres and the absence of centralized
interpretation, reflecting daily practice.
Methods
Registry design
Sixty‐nine centres from 18 countries participated in this pro-
spective, observational European multinational and
multicentre registry on adult patients with cardiom
yopathies.7,8 The registry consists of Pilot and Long‐term
phases. The centres invited to the Pilot phase were selected
as highly expert centres in myocardial diseases. Enrollment
of adult patients with cardiomyopathies took place between
December 2012 and November 2013 for the Pilot Registry
and between June 2014 and December 2016 for the Long‐
term Registry. Each centre provided about 40 consecutive
adult cardiomyopathy patients over 1 year period. The ap-
provals of local ethics committees were obtained by each
participating centre. Written informed consent was required
before including the patient into the registry. The study com-
plies with the Declaration of Helsinki. Diagnostic and treat-
ment decisions were solely performed by the attending
physician. The registry has been conducted by the executive
committee, whereas the management of the study, data
quality control, and statistical analyses have been carried
out by the EURObservational Research Programme depart-
ment of the ESC.
Patients
The inclusion criteria for the adult cardiomyopathy registry
were age at enrollment,>18 years, written informed consent
from the patient, ability to comply with the study require-
ments, and a documented cardiomyopathy, which fulfilled
the study criteria for probands or relatives.
Definitions of cardiomyopathies, subgroups, and geo-
graphical areas have been previously published.7,8 The pa-
tient population reported here comprises 3208 consecutive
adult patients, with hypertrophic cardiomyopathy (HCM,
n = 1739), dilated cardiomyopathy (DCM, n = 1260), arrhyth-
mogenic right ventricular cardiomyopathy (ARVC, n = 143),
and restrictive cardiomyopathy (RCM, n = 66). Although the
concept of arrhythmogenic cardiomyopathy has recently
been introduced, the term ‘ARVC’ is still used here because
of the planned strict inclusion criteria. The baseline clinical
characteristics of the patients have been published earlier.7,8
Genetic testing and findings
The inclusion of patients in the registry had no impact on the
management of the patient by the local investigators. The
data we studied therefore reflect the local practice of centres
at this era, which was the focus of the study. As a conse-
quence, heterogeneous molecular analyses were performed
by centres, with a range of genetic testing techniques from
sequencing after Sanger to large‐scale next‐generation
sequencing.9 The data on genetic findings collected into the
case report form comprised the genes tested, and recorded
variants were described using either nucleotide or amino acid
alterations. These variants had been classified independently
by each centre/investigator as to wild type, variant of un-
known significance (VUS), or probably disease‐causing variant
(DCV). It should be noted that systematic American College of
Medical Genetics and Genomics classification scheme was
not available at the beginning of patient enrollment, and
thus, we use here the term DCV instead of the ‘pathogenic’
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or ‘likely pathogenic’ American College of Medical Genetics
and Genomics terms to define variants.9
Statistical analyses
Univariate analysis was applied to both continuous and cate-
gorical variables. Continuous variables were reported as
mean ± standard deviation and/or as median and interquar-
tile range when appropriate. Among‐group comparisons
were made using the non‐parametric test (Kruskal–Wallis
test). Categorical variables were reported as percentages.
Among‐group comparisons were made using the χ2 test or
a Fisher’s exact test if any expected cell count was <5. A
two‐sided P‐value of<0.05 was considered as statistically sig-
nificant. All analyses were performed using SAS statistical
software version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Genetic counselling
Information on whether genetic counselling was performed
or not was available for 91.6% of the population (2939/
3208 patients), and data on whether the patient was an index
patient or a relative were available for 2324/3208 (72.4%) of
all the participants. Genetic counselling was performed in
1786/2939 (60.8%) of all patients, 1077/1760 (61.2%) of in-
dex patients, and 315/376 (83.8%) of relatives. When all pa-
tients were considered, the main clinical features associated
with genetic counselling were younger age at diagnosis [me-
dian (Q1–Q3): 45 (32–57) vs. 52 (41–61) years, P < 0.001],
gender (P = 0.04), family history of SCD (19.9% vs. 13.2%,
P < 0.001), and familial disease (51.5% vs. 18.6%,
P < 0.001). The patients receiving counselling had fewer
co‐morbidities and alcohol use than those who were not
counselled (Supporting Information, Table S1). In index pa-
tients, clinical features associated with genetic counselling
were younger age at diagnosis [median (Q1–Q3): 46 (34–57)
vs. 52 (42–61) years], higher proportion of familial disease
(47.7% vs. 16.6%), and less symptoms (66.4% vs. 83.1%)
(P < 0.001 for each comparison). Supporting Information, Ta-
ble S2 shows the proportions of patients with genetic
counselling and with or without genetic testing.
When geographical areas were considered, genetic
counselling was performed in 42.4% of all patients in West
Europe, 56.7% in North Europe, 58.7% in East Europe,
67.8% in South Europe, and 83.3% of patients from a single
centre in North Africa (Table 1). When cardiomyopathy sub-
types were considered, genetic counselling was provided to
1221/1619 (75.4%) of HCM, 442/1127 (39.2%) of DCM,
92/130 (70.8%) of ARVC, and for 31/63 (49.2%) of RCM pa-
tients (P < 0.001). Genetic counselling was provided by a
cardiologist for 85.3%, by a geneticist for 15.1%, by a genetic
counsellor for 11.3%, and by a nurse for 7.5% of counselled
subjects (Table 1). Cardiologists were predominantly involved
in all geographical regions except in West Europe where
geneticists/genetic counsellors were predominant (Table 1).
Genetic testing
Information on whether genetic testing was performed or
not was available for 92.4% (2963) of the patients, including
index patients, relatives, and those with unknown family sta-
tus. Genetic testing was carried out in 1105/2963 (37.3%) of
all adult cardiomyopathy patients. It was performed less fre-
quently in index patients (643/1772, 36.3%) as compared
with relatives (234/376, 62.2%, P < 0.001). Genetic testing
was carried out more frequently in the Pilot (selected as
highly expert centres) as compared with the Long‐term
phases (centres with variable degree of expertise) (43.9%
vs. 33.8%, P < 0.001). The clinical features of all index pa-
tients with or without genetic testing are shown in Table 2.
The index patients with genetic testing were younger at diag-
nosis [median (Q1–Q3): 45 (33–57) vs. 50 (40–59) years,
P < 0.001], more frequently male (63.6% of index patients
were male; genetic testing performed in 39.5% of female pa-
tients and 34.7% of male patients, P = 0.04), more often had
familial disease (60.0% vs. 22.0%, P < 0.001) or family history
of SCD (21.7% vs 10.8%, P < 0.001), had implantable
cardioverter defibrillators (30.5% vs. 20.6%, P < 0.001), and
had less often hypertension (30.6% vs. 43.3%, P < 0.001),
type 2 diabetes (8.9% vs. 14.3%, P < 0.001), or alcohol use
(17.4% vs. 44.4%, P < 0.001) as compared with those
without.
Table 1 shows the extremely wide range in the degree of
genetic testing between predetermined geographical regions:
49.7% in South Europe, 40.4% in West Europe, 34.6% in
North Europe, 15.2% in East Europe, and 0% in North Africa
(P < 0.001). In index patients, genetic testing was performed
differently according to cardiomyopathy subtypes
(P < 0.001): in 462/967 (47.8%) of HCM, 132/697 (18.9%)
of DCM, 35/71 (49.3%) of ARVC, and 14/37 (37.8%) of RCM
index patients (Table 3). In contrast, genetic testing was fre-
quently performed in relatives (>56%) without significant dif-
ferences among cardiomyopathy subtypes (Table 3).
Genetic results
Results of genetic testing were reported for all 643 index pa-
tients with genetic testing performed. At least one DCV was
reported in 41.7% of all tested index patients (Table 4). Two
or more DCVs were found in <2% of the probands. At least
one VUS was found in 17.3% of all index cases. Regarding
the cardiomyopathy subtypes, one or more DCVs were found
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in 43.3% of HCM, 33.3% of DCM, 51.4% of ARVC, and 42.9%
of RCM index patients (P = 0.13).
Supporting Information, Table S3 shows the genes tested
in HCM patients and the reported yields of DCVs and VUSs
per individual gene tested. Mutations were most frequently
identified in MYBPC3, MYH7, and TNNT2 genes. HCM index
patients with at least one DCV, as compared with those with
none, were younger at diagnosis [median (Q1–Q3): 39 (27–
31) vs. 50 (39–60) years, P < 0.001) and more often had fa-
milial disease (75.1% vs. 46.9%, P < 0.001), asymmetrical
septal hypertrophy (83.7% vs. 71.1%, P = 0.002), ventricular
arrhythmias (14.5% vs. 5.0%, P < 0.001), or an implanted
cardioverter defibrillator (33.0% vs. 14.5%, P < 0.001) (not
shown). They less often had hypertension (26.0% vs. 42.4%,
P < 0.001), hyperlipidaemia (29.5% vs. 43.9%, P = 0.002),
or significant left ventricular outflow tract gradient at rest
(16.8% vs. 30.5%, P = 0.02) (not shown).
Supporting Information, Table S4 shows the genes tested
in DCM patients and their reported yields of DCVs and VUSs
per individual gene tested. Mutations were most frequently
identified in MYH7, TCAP, LMNA, and MYBPC3. In titin gene
(TTN), a DCV was found only in 3 out of 56 (5.4%) tested pa-
tients. DCM index patients with at least one DCV had more
often familial disease (72.2% vs. 47.6%, P = 0.018) and
extracardiac signs (33.3% vs. 10.3%, P = 0.003) (not shown).
In ARVC index patients, Supporting Information, Table S5
describes the number of DCVs and VUSs per gene related
to the total number of patients genotyped for any of the
genes. DCVs were most frequently identified in PKP2,
DSG2, and DSC2.
In RCM, 14 probands underwent genetic testing. DCVs
were reported in DES, GLA, MYBPC3, TNNT2, and TTN, one
in each gene.
Discussion
We report the first detailed study of the practice of genetic
counselling and testing in cardiomyopathies in Europe. The
data were prospectively collected on consecutive patients
from a large range of centres between December 2012 and
December 2016. They reflect contemporary management
of cardiomyopathy patients and local practices in the context
of existing recommendations on these issues by various aca-
demic societies.
Genetic counselling
We observed that genetic counselling was provided in
two‐thirds of patients and to a lesser extent to index patients
as compared with relatives. The total number of counselled
patients was lower than expected given severalTa
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recommendations published from 2010 to promote genetic
counselling in cardiomyopathies.3–6,10
In this registry, those individuals who received counselling
were younger and more often had familial disease. However,
older patients should also be counselled, especially in the
context of increasingly recognized diseases, which occur at
later age such as familial TTR amyloidosis or Fabry disease.
Similarly, the familial context may be absent in the case of
de novo mutation and or a mutation transmitted by a parent
with a non‐penetrant mutation. Genetic counselling was per-
formed less frequently in DCM patients as compared with
other subtypes, although DCM is now considered to be famil-
ial or genetic in at least 30–50% of cases. The proportion of
counselled patients greatly varied in different geographical
Table 3 Genetic testing performed in separate cardiomyopathy groups
HCM (n = 1739) DCM (n = 1260) ARVC (n = 143) RCM (n = 66) All (n = 3208) P‐value
Index patients, n (%) 462/967 (47.8) 132/697 (18.9) 35/71 (49.3) 14/37 (37.8) 643/1772 (36.3) <0.001
Relatives, n (%) 166/263 (63.1) 50/88 (56.8) 16/23 (69.6) 2/2 (100.0) 234/376 (62.2) 0.48
All,a n (%) 789/1616 (48.8) 214/1150 (18.6) 75/135 (55.6) 27/62 (43.6) 1105/2963 (37.3) <0.001
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; RCM, re-
strictive cardiomyopathy.
aIncluding index patients and relatives and those unknown for the family status, whether they were index patients or probands.
Table 4 DCV and VUS in index patients according to cardiomyopathy subtypes
HCM (n= 462)DCM (n= 132)ARVC (n= 35)RCM (n= 14)All index patients (n= 643) P‐
value
At least one DCV, n (%) 200/462 (43.3)44/132 (33.3) 18/35 (51.4) 6/14 (42.9) 268/643 (41.7) 0.13
At least two DCVs, n (%) 8/462 (1.7) 3/132 (2.3) 1/35 (2.9) 0/14 (0.0) 12/643 (1.9) 0.72
At least one VUS, n (%) 65/462 (14.1) 37/132 (28.0) 8/35 (22.9) 1/14 (7.1) 111/643 (17.3) 0.001
At least one VUS in patient with a DCV, n (%)12/200 (6.0) 8/44 (18.2) 3/18 (16.7) 0/6 (0.0) 23/268 (8.6) 0.03
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; DCV, disease‐causing variants; HCM, hypertro-
phic cardiomyopathy; RCM, restrictive cardiomyopathy; VUS, variant of unknown significance.
Table 2 Clinical characteristics of all adult cardiomyopathy index patients with or without genetic testing performed
Genetic testing performed (n = 643) Genetic testing not performed (n = 1129) P‐value
Age at enrollment (years), n Median (Q1–Q3) 55 (43–65) 55 (45–64) 0.27
Age at diagnosis (years), n Median (Q1–Q3) 45 (33–57) 50 (40–59) <0.001
Female, n (%) 234/592 (39.5) 358/592 (60.5) 0.04
Male, n (%) 409/1180 (34.7) 771/1180 (65.3)
Family history of SCD, n (%) 133/612 (21.7) 114/1052 (10.8) <0.001
Familial disease, n (%) 296/493 (60.0) 194/882 (22.0) <0.001
SCD/cardiac arrest, n (%) 15/587 (2.6) 13/1087 (1.2) 0.04
NYHA class, n (%)
NYHA I 147/486 (30.3) 171/956 (17.9)
NYHA II 239/486 (49.2) 481/956 (50.3)
NYHA III 94/486 (19.3) 258/956 (27.0)
NYHA IV 6/486 (1.2) 46/956 (4.8) <0.001
Hypertension, n (%) 197/643 (30.6) 489/1129 (43.3) <0.001
Diabetes Type 1, n (%) 3/643 (0.5) 5/1129 (0.4) 1.0
Diabetes Type 2, n (%) 57/643 (8.9) 161/1129 (14.3) <0.001
Hyperlipidaemia/dyslipidaemia, n (%) 223/643 (34.7) 546/1129 (48.4) <0.001
Renal impairment, n (%) 70/643 (10.9) 158/1129 (14.0) 0.06
Alcohol use (yes/no), n (%) 83/478 (17.4) 445/1002 (44.4) <0.001
Skeletal muscle impairment, n (%) 21/643 (3.3) 49/1129 (4.3) 0.26
AV block,a n (%) 102/531 (19.2) 163/1057 (15.4) 0.06
Atrial fibrillation of flutter, n (%) 193/643 (30.0) 314/1129 (27.8) 0.32
Ventricular arrhythmias, n (%) 85/643 (13.2) 138/1129 (12.2) 0.54
Associated LV non‐compaction, n (%) 29/636 (4.6) 44/1103 (4.0) 0.57
Pacemaker implanted, n (%) 73/637 (11.5) 116/1126 (10.3) 0.45
Cardioverter defibrillator implanted, n (%) 196/643 (30.5) 232/1129 (20.6) <0.001
Cardiac medication, n (%) 487/534 (91.2) 857/928 (92.4) 0.44
AV, atrioventricular; LV, left ventricular; NYHA, New York Heart Association; SCD, sudden cardiac death.
All sample size includes index patients with or without genetic testing (those with data lacking on genetic testing were excluded).
aAV block includes history of AV block or first‐degree, second‐degree, or third‐degree block.
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areas, suggesting an area of potential improvement especially
for some European regions. The registry also provided infor-
mation on the person who gave genetic counselling. Cardiol-
ogists were most often involved except for West Europe
where genetic counselling was mostly provided by genetic
counsellors and geneticists. This may reflect heterogeneous
availability of genetic counsellors and geneticists in different
countries or individual practices of the participating centres.
The scope of genetic counselling has been detailed in previ-
ous recommendations3–6,10 and should include information
about the genetic origin of cardiomyopathies, the mode of in-
heritance and the potential risk for relatives, who carry the
mutation, the natural history with frequent delayed cardiac
onset, the benefits and organization of a cardiac screening
within the family, the risk of worsening of the disease during
pregnancy, availability of genetic testing, medical sources of
information, and existing patient associations. Unfortunately,
we do not have more detailed data on the contents of the ge-
netic counselling delivered by centres or on a possible specific
board qualification when cardiologists were involved. To de-
velop dedicated training for cardiologists may be an area for
improvement.
Genetic testing
Genetic testing was performed in about one‐third of index
patients and over half of the relatives. This low proportion
of genetic testing is not in line with the existing
recommendations.3–6,10 For example, in an ESC Working
Group statement3 where genetic testing is recommended in
all index patients with definite clinical diagnosis of a cardio-
myopathy, to enable predictive diagnosis in first‐degree rela-
tives according to a cascade screening strategy, and when a
specific aetiology of cardiomyopathy is suspected in the index
patient in order to confirm the specific cause and appropri-
ately manage the patient and the family. It should be noticed
that the relatives included in this registry fulfilled the diagnos-
tic criteria of clinical cardiomyopathy, and thus, genetic test-
ing has been diagnostic, not predictive.
About two‐thirds of the index patients were male, which
may reflect the natural course of cardiomyopathies with de-
layed expression in female patients. Index patients who were
genetically tested were younger at diagnosis, more often had
familial disease or family history of SCD, and fewer
co‐morbidities as compared with those who were not genet-
ically tested. Genetic testing was also less frequently per-
formed in DCM patients as compared with other subtypes.
The fact that DCM was under‐investigated might be related
to the heterogeneous aetiology of the disease with many ac-
quired causes2,10–13but may also be related to the low yield
of mutation identification until recently when the prominent
role of TTN was recognized along with the development of
high‐throughput sequencing.14–16 Large regional differences
were observed in genetic testing with the lowest rates in East
Europe and North Africa. They possibly reflect geographical
differences in economic status of the countries or variable in-
surance modalities for covering the costs of genetic testing.
Genetic findings
The yield of genetic testing was relatively high with ~42%
of tested index patients having at least one DCV. However,
the interpretation of these data should be cautious and
considered only as exploratory because results were
self‐reported by investigators who used various sequencing
methods (from focused Sanger sequencing to small or large
high‐throughput sequencing panels) with a local classifica-
tion of variants’ pathogenicity determined at the time of
inclusion.
Nevertheless, in HCM index patients, a DCV was found in
43.3% of cases, in agreement with the usual figure of 30–
60% according to populations studied and genes
investigated.17,18 HCM results also support the major role of
sarcomeric genes.18 In DCM, the proportion of index patients
with a DCV was one‐third, which is relatively low but consis-
tent with the fact that TTN gene, now recognized as the ma-
jor gene in DCM, was analysed in only few patients in our
population, probably because high‐throughput sequencing
of this gene was not yet widely available at that moment.14–
16 In ARVC patients, a DCV was identified in half of the pa-
tients in line with the current literature.19,20 There were
few patients with RCM, and the results of genetic testing sup-
port earlier observations on the heterogeneous genetic
background.21
Perspectives
Altogether, our results show that the translation of guide-
lines or position statements about genetic
counselling/testing into clinical practice is substantial but
still needs to be improved. This is especially important in
the field of cardiomyopathies because genetics is a key tool
for the improvement of patients and family management
through personalized medicine as illustrated by family cas-
cade screening strategy or refined prognosis stratification
along with the development of recent innovative therapeu-
tics based on new small molecules or gene‐editing ap-
proaches. 22,23
We consistently identified determinants of genetic
counselling/testing practice per se as it was performed more
often in patients who are younger, had more familial
disease/family history of SCD, less co‐morbidities, and less of-
ten in DCM as compared with other subtypes. These determi-
nants are meaningful because they are usually also predictors
of the yield of genetic sequencing in cardiomyopathies, and
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interestingly, we also identified these predictors for mutation
identification rate in HCM patients.24 However, to restrict ge-
netic counselling/testing to this subpopulation is misleading
because there is an increasing evidence for important genetic
component in patients who are older (role of TTR amyloidosis
for example) or who have DCM14–16 or peripartum
cardiomyopathy.25 Further efforts are needed to offer ge-
netic counselling/testing to a larger proportion of patients
with a cardiomyopathy, whatever age, familial status, or co‐
morbidities.
We also observed large heterogeneity in European regions,
and it can be hypothesized that variations in service provision
are mostly related to economical or structural reasons. To
promote a dedicated organization of healthcare systems for
hereditary diseases, including cardiomyopathies, at a national
or European level is suggested, and initiatives underway such
as the European Reference Network for Rare and Low Preva-
lence Complex Diseases of the Heart (ERN GUARD‐Heart for
cardiac disease, https://guardheart.ern‐net.eu/) should be
supported.
Finally, a better organization of healthcare system at lo-
cal level is probably another way to progress. To identify
and build dedicated multidisciplinary heart teams might
be useful as shown in other areas.26 The fact that genetic
counselling was performed by cardiologist in 85% of cases
in our study supports the proposal of more interactions
with other disciplines such as clinical geneticists. Another
way to achieve the objective may be to construct and dif-
fuse clinical integrated care pathways for cardiomyopathy
patients as a tool used to manage the quality in healthcare
and diffuse the standardization of care processes.27
Study limitations
This observational registry study provides innovative data
but has several limitations. Some data were missing such
as family status (index patients or relatives) for about
one‐fifth of patients who were therefore excluded from
part of analyses about genetic testing. The content of ge-
netic counselling that was delivered was not recorded in
the case report form and thus not studied. The genetic re-
sults should be considered as exploratory because of the
heterogeneous molecular methods used by the various cen-
tres and the variable listing of genes. In addition, the clas-
sification of the genetic variants was purely based on the
data provided by the participating centres. As detailed orig-
inal genetic molecular data about the variants have not
been gathered in this registry, it was not possible to reclas-
sify the variants according to current standards. We cannot
exclude that some variants were misclassified, especially in
the context of evolving knowledge and rules about inter-
pretation of genetic variants.
Conclusions
This is the first detailed report on the real‐life practice of ge-
netic counselling and testing in cardiomyopathies in Europe.
Genetic counselling and testing were performed in a substan-
tial proportion of patients but less than expected by Euro-
pean guidelines. European regional differences in providing
counselling and testing were considerable and differed be-
tween cardiomyopathy phenotypes.
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